Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
A phase 1/2 trial of Directional Brachytherapy Source Implant in pancreatic ductal adenocarcinoma, run by CivaTech Oncology, now recruiting.
Overview
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source is a phase 1/2 interventional study registered as NCT02843945 by CivaTech Oncology, with 80 participants planned, started 2017-05-31 and due to reach its primary completion in 2027-10-29. Interventions recorded: Directional Brachytherapy Source Implant.
Similar pages
not linked directly; found by shared links- TrialFeasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Shares CivaTech Oncology and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialRecombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.